- Home
- SLGL vs RANI Comparison
SLGL vs RANI Comparison
Compare SLGL & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- RANI
- Stock Information
- Founded
- SLGL 1997
- RANI 2012
- Country
- SLGL Israel
- RANI United States
- Employees
- SLGL N/A
- RANI N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- SLGL Health Care
- RANI Health Care
- Exchange
- SLGL Nasdaq
- RANI Nasdaq
- Market Cap
- SLGL 19.3M
- RANI 19.6M
- IPO Year
- SLGL 2018
- RANI 2021
- Fundamental
- Price
- SLGL $7.26
- RANI $0.56
- Analyst Decision
- SLGL Buy
- RANI Strong Buy
- Analyst Count
- SLGL 1
- RANI 4
- Target Price
- SLGL $40.00
- RANI $7.75
- AVG Volume (30 Days)
- SLGL 25.3K
- RANI 287.9K
- Earning Date
- SLGL 08-15-2025
- RANI 08-05-2025
- Dividend Yield
- SLGL N/A
- RANI N/A
- EPS Growth
- SLGL N/A
- RANI N/A
- EPS
- SLGL N/A
- RANI N/A
- Revenue
- SLGL $12,103,000.00
- RANI $1,200,000.00
- Revenue This Year
- SLGL N/A
- RANI N/A
- Revenue Next Year
- SLGL $31.17
- RANI N/A
- P/E Ratio
- SLGL N/A
- RANI N/A
- Revenue Growth
- SLGL 603.66
- RANI N/A
- 52 Week Low
- SLGL $3.34
- RANI $0.46
- 52 Week High
- SLGL $16.50
- RANI $4.19
- Technical
- Relative Strength Index (RSI)
- SLGL 52.97
- RANI 35.97
- Support Level
- SLGL $7.02
- RANI $0.51
- Resistance Level
- SLGL $7.58
- RANI $0.56
- Average True Range (ATR)
- SLGL 0.37
- RANI 0.03
- MACD
- SLGL 0.02
- RANI 0.01
- Stochastic Oscillator
- SLGL 41.28
- RANI 21.50
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.